167 related articles for article (PubMed ID: 15623654)
21. Lack of pantoprazole drug interactions in man.
Steinijans VW; Huber R; Hartmann M; Zech K; Bliesath H; Wurst W; Radtke HW
Int J Clin Pharmacol Ther; 1994 Aug; 32(8):385-99. PubMed ID: 7981922
[TBL] [Abstract][Full Text] [Related]
22. Comparative pharmacokinetic/pharmacodynamic study of proton pump inhibitors, omeprazole and lansoprazole in rats.
Katashima M; Yamamoto K; Sugiura M; Sawada Y; Iga T
Drug Metab Dispos; 1995 Jul; 23(7):718-23. PubMed ID: 7587960
[TBL] [Abstract][Full Text] [Related]
23. Selective inhibition of the gastric H+,K(+)-ATPase by omeprazole and related compounds.
Lorentzon P; Bayati A; Lee H; Andersson K
Ann N Y Acad Sci; 1997 Nov; 834():592-9. PubMed ID: 9405870
[No Abstract] [Full Text] [Related]
24. Augmentation of myelopoiesis in a murine host bearing a T cell lymphoma following in vivo administration of proton pump inhibitor pantoprazole.
Vishvakarma NK; Singh SM
Biochimie; 2011 Oct; 93(10):1786-96. PubMed ID: 21722701
[TBL] [Abstract][Full Text] [Related]
25. Pharmacodynamic comparison of pantoprazole enantiomers: inhibition of acid-related lesions and acid secretion in rats and guinea-pigs.
Cao H; Wang MW; Sun LX; Ikejima T; Hu ZQ; Zhao WH
J Pharm Pharmacol; 2005 Jul; 57(7):923-7. PubMed ID: 15969954
[TBL] [Abstract][Full Text] [Related]
26. The gastric H,K-ATPase blocker lansoprazole is an inhibitor of chloride channels.
Schmarda A; Dinkhauser P; Gschwentner M; Ritter M; Fürst J; Scandella E; Wöll E; Laich A; Rossmann H; Seidler U; Lang F; Paulmichl M
Br J Pharmacol; 2000 Feb; 129(3):598-604. PubMed ID: 10711360
[TBL] [Abstract][Full Text] [Related]
27. Pharmacodynamic effects of 3-day intravenous treatment with pantoprazole or ranitidine after 10 days of oral ranitidine.
Ley LM; Becker A; Lühmann R; Sander P; Lücker PW
Methods Find Exp Clin Pharmacol; 2005; 27(1):25-9. PubMed ID: 15834456
[TBL] [Abstract][Full Text] [Related]
28. Effect of pantoprazole administered subcutaneously on the healing of sutured gastric incisions in rats.
Bonin EA; Campos AC; Coelho JC; Matias JE; Malafaia O; Jonasson TH
Eur Surg Res; 2005; 37(4):250-6. PubMed ID: 16260877
[TBL] [Abstract][Full Text] [Related]
29. KRC-408, a novel c-Met inhibitor, suppresses cell proliferation and angiogenesis of gastric cancer.
Hong SW; Jung KH; Park BH; Zheng HM; Lee HS; Choi MJ; Yun JI; Kang NS; Lee J; Hong SS
Cancer Lett; 2013 May; 332(1):74-82. PubMed ID: 23348694
[TBL] [Abstract][Full Text] [Related]
30. In vivo cytochrome P 450 interactions of the newly developed H+/K(+)-ATPase inhibitor pantoprazole (BY 1023/SK&F 96022) compared to other antiulcer drugs.
Hanauer G; Graf U; Meissner T
Methods Find Exp Clin Pharmacol; 1991; 13(1):63-7. PubMed ID: 1651432
[TBL] [Abstract][Full Text] [Related]
31. The proton-pump inhibitors: similarities and differences.
Horn J
Clin Ther; 2000 Mar; 22(3):266-80; discussion 265. PubMed ID: 10963283
[TBL] [Abstract][Full Text] [Related]
32. Effects of pantoprazole as a HIF-1α inhibitor on human gastric adenocarcinoma sgc-7901 cells.
Shen Y; Wu Y; Chen M; Shen W; Huang S; Zhang L; Zou X
Neoplasma; 2012; 59(2):142-9. PubMed ID: 22248271
[TBL] [Abstract][Full Text] [Related]
33. Pantoprazole versus omeprazole: influence on meal-stimulated gastric acid secretion.
Dammann HG; Burkhardt F
Eur J Gastroenterol Hepatol; 1999 Nov; 11(11):1277-82. PubMed ID: 10563540
[TBL] [Abstract][Full Text] [Related]
34. Proton pump activation in stimulated parietal cells is regulated by gastric acid secretory capacity: a human study.
Metz DC; Ferron GM; Paul J; Turner MB; Soffer E; Pisegna JR; Bochenek WJ
J Clin Pharmacol; 2002 May; 42(5):512-9. PubMed ID: 12017345
[TBL] [Abstract][Full Text] [Related]
35. Proton pump inhibitors.
Grover JK; Vats V
Trop Gastroenterol; 1999; 20(1):16-28. PubMed ID: 10464444
[No Abstract] [Full Text] [Related]
36. Optimizing the intragastric pH as a supportive therapy in upper GI bleeding.
Brunner G; Luna P; Hartmann M; Wurst W
Yale J Biol Med; 1996; 69(3):225-31. PubMed ID: 9165691
[TBL] [Abstract][Full Text] [Related]
37. [Submicroscopic aspects of the mechanism of inhibitors of H+/K+-ATPase in gastric parietal cells].
Morozov IA
Eksp Klin Gastroenterol; 2002; (3):94-100, 122. PubMed ID: 12353402
[TBL] [Abstract][Full Text] [Related]
38. Lack of pantoprazole drug interactions in man: an updated review.
Steinijans VW; Huber R; Hartmann M; Zech K; Bliesath H; Wurst W; Radtke HW
Int J Clin Pharmacol Ther; 1996 May; 34(1 Suppl):S31-50. PubMed ID: 8793602
[TBL] [Abstract][Full Text] [Related]
39. Pantoprazole lacks interaction with antipyrine in man, either by inhibition or induction.
De Mey C; Meineke I; Steinijans VW; Huber R; Hartmann M; Bliesath H; Wurst W
Int J Clin Pharmacol Ther; 1994 Feb; 32(2):98-106. PubMed ID: 8004366
[TBL] [Abstract][Full Text] [Related]
40. Pantoprazole does not interact with nifedipine in man under steady-state conditions.
Bliesath H; Huber R; Steinijans VW; Koch HJ; Kunz K; Wurst W
Int J Clin Pharmacol Ther; 1996 May; 34(1 Suppl):S81-5. PubMed ID: 8793608
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
